SHINE, Orano Sign MOU for Pilot Plant
SHINE Technologies has signed a Memorandum of Understanding (MOU) with Orano to cooperate in the development of the U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from…
SHINE Technologies has signed a Memorandum of Understanding (MOU) with Orano to cooperate in the development of the U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from…
SHINE Technologies has raised $70 million in additional funding to accelerate the commercialization of near-term applications of fusion technology, the company announced today. The round was led by existing investors…
SHINE Technologies has demonstrated clearly visible Cherenkov radiation produced by fusion for what is believed to be the first time in history, the company announced today. “Fusion has long captured…
SHINE Technologies announced today it is opening the largest facility in North America dedicated to producing a medical isotope used in targeted cancer therapies. According to a release, the facility,…
SHINE Technologies is now offering state-of-the-art radiation effects testing, the company announced today. According to a release, the service, called FLARE (Fusion Linear Accelerator for Radiation Effects), will use high-energy…
Presentations, Pitches 12:15 -1 p.m. Wednesday, Feb. 15 at UW-Madison Grainger Hall — Distinguished Entrepreneurs Lunch: Judy McNeal 7:30-9 a.m. Thursday, Feb. 16 at Edgewater Hotel — Cap Times: Executive…
SHINE Technologies named Tom D’Orazio as the CEO of Phoenix, the company announced recently. According to a release, D’Orazio has more than two decades of experience in sales leadership roles…
SHINE Technologies has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, the company announced recently. According to a release, the…
SHINE Technologies announced recently that Holli C. Ladhani and Janet S. Wong have joined its board of directors. “We are excited to bring these two highly talented individuals to our…
SHINE Technologies announced recently that it will supply ImaginAb Inc., a global biotechnology company focused on developing immuno-oncology imaging agents and therapeutic radiopharmaceuticals, with lutetium-177 (Lu-177) to support the company’s…